靶向肿瘤相关巨噬细胞的抗肿瘤策略研究进展
Advances in Antitumor Strategies Targeting Tumor-Associated Macrophages
DOI: 10.12677/WJCR.2022.121004, PDF,  被引量   
作者: 杨 枫, 张 琨:中国人民解放军92318部队,北京;王 蕊*:中日友好医院,北京
关键词: 肿瘤相关巨噬细胞肿瘤免疫肿瘤治疗抗肿瘤Tumor Associated Macrophages Tumor Immunity Tumor Therapy Anti-Tumor
摘要: 肿瘤相关巨噬细胞(tumor associated macrophages, TAMs)是大多数肿瘤中浸润最多的一类免疫细胞,在肿瘤发生、发展和转移中均发挥关键性作用。TAMs具有较强的异质性与可塑性。受肿瘤微环境(Tumor Microenvironment, TME)复杂因子的影响,TAMs呈现不同的表型与功能,主要包括抑肿瘤的M1样TAMs和促肿瘤的M2样TAMs。大多数肿瘤中,TAMs呈现M2样表型,通过促进血管生成、抑制细胞毒性T细胞浸润和功能活化、诱导调节性T细胞、产生基质金属蛋白酶等机制抑制肿瘤免疫微环境,从而促进肿瘤的发生、发展和转移。因此,靶向TAMs已成为肿瘤免疫治疗的潜在重要手段。本文主要综述了目前已有的靶向TAMs的治疗策略和研究进展。
Abstract: Tumor-associated macrophages (TAMs) are the most infiltrating class of immune cells in most tumors and play a key role in tumor development, progression and metastasis. TAMs have strong heterogeneity and plasticity. Influenced by the complex factors of tumor microenvironment (TME), TAMs present different phenotypes and functions, including M1-like TAMs that inhibit tumors and M2-like TAMs that promote tumors. In most tumors, TAMs present an M2-like phenotype and inhibit the tumor immune microenvironment by promoting angiogenesis, inhibiting cytotoxic T cell infiltration and functional activation, inducing regulatory T cells, and producing matrix metalloproteinases, thereby promoting tumor development, progression, and metastasis. Therefore, targeted TAMs have become a potentially important means of cancer immunotherapy. This review focuses on the existing therapeutic strategies and research progress of targeted Tams.
文章引用:杨枫, 张琨, 王蕊. 靶向肿瘤相关巨噬细胞的抗肿瘤策略研究进展[J]. 世界肿瘤研究, 2022, 12(1): 23-32. https://doi.org/10.12677/WJCR.2022.121004

参考文献

[1] Ceci, C., et al. (2020) Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers (Basel), 12, Article 3401.
[Google Scholar] [CrossRef] [PubMed]
[2] Liu, Z., et al. (2019) Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells. Cell, 178, 1509- 1525e19.
[Google Scholar] [CrossRef] [PubMed]
[3] Ginhoux, F., et al. (2010) Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages. Science, 330, 841-845.
[Google Scholar] [CrossRef] [PubMed]
[4] Guilliams, M., et al. (2013) Alveolar Macrophages Develop from Fetal Monocytes That Differentiate into Long-Lived Cells in the First Week of Life via GM-CSF. Journal of Experimental Medicine, 210, 1977-1992.
[Google Scholar] [CrossRef] [PubMed]
[5] Bain, C.C., et al. (2014) Constant Replenishment from Circulating Monocytes Maintains the Macrophage Pool in the Intestine of Adult Mice. Nature Immunology, 15, 929-937.
[Google Scholar] [CrossRef] [PubMed]
[6] Liu, Y. and Cao, X. (2015) The Origin and Function of Tumor-Associated Macrophages. Cellular & Molecular Immunology, 12, 1-4.
[Google Scholar] [CrossRef] [PubMed]
[7] Biswas, S.K. and Mantovani, A. (2010) Macrophage Plasticity and Interaction with Lymphocyte Subsets: Cancer as a Paradigm. Nature Immunology, 11, 889-896.
[Google Scholar] [CrossRef] [PubMed]
[8] Bottazzi, B., et al. (1983) Regulation of the Macrophage Content of Neoplasms by Chemoattractants. Science, 220, 210-212.
[Google Scholar] [CrossRef] [PubMed]
[9] Qian, B.Z. and Pollard, J.W. (2010) Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell, 141, 39-51.
[Google Scholar] [CrossRef] [PubMed]
[10] Hambardzumyan, D., Gutmann, D.H. and Kettenmann, H. (2016) The Role of Microglia and Macrophages in Glioma Maintenance and Progression. Nature Neuroscience, 19, 20-27.
[Google Scholar] [CrossRef] [PubMed]
[11] Qian, B.Z., et al. (2011) CCL2 Recruits Inflammatory Monocytes to Facilitate Breast-Tumour Metastasis. Nature, 475, 222-225.
[Google Scholar] [CrossRef] [PubMed]
[12] Loyher, P.L., et al. (2018) Macrophages of Distinct Origins Contribute to Tumor Development in the Lung. Journal of Experimental Medicine, 215, 2536-2553.
[Google Scholar] [CrossRef] [PubMed]
[13] Zhu, Y., et al. (2017) Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity, 47, 323-338.e6.
[Google Scholar] [CrossRef] [PubMed]
[14] Bowman, R.L., et al. (2016) Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Reports, 17, 2445-2459.
[Google Scholar] [CrossRef] [PubMed]
[15] Chen, Z., et al. (2017) Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. Cancer Research, 77, 2266-2278.
[Google Scholar] [CrossRef
[16] DeNardo, D.G. and Ruffell, B. (2019) Macrophages as Regulators of Tumour Immunity and Immunotherapy. Nature Reviews Immunology, 19, 369-382.
[Google Scholar] [CrossRef] [PubMed]
[17] Kumar, V., et al. (2016) CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity, 44, 303-315.
[Google Scholar] [CrossRef] [PubMed]
[18] Noy, R. and Pollard, J.W. (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity, 41, 49-61.
[Google Scholar] [CrossRef] [PubMed]
[19] Pollard, J.W. (2009) Trophic Macrophages in Development and Disease. Nature Reviews Immunology, 9, 259-270.
[Google Scholar] [CrossRef] [PubMed]
[20] Morandi, F. and Pistoia, V. (2014) Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions. Frontiers in Immunology, 5, Article 394.
[Google Scholar] [CrossRef] [PubMed]
[21] Santarpia, M. and Karachaliou, N. (2015) Tumor Immune Microenvironment Characterization and Response to Anti-PD-1 Therapy. Cancer Biology & Medicine, 12, 74-78.
[22] Buchbinder, E.I. and Desai, A. (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology, 39, 98-106.
[Google Scholar] [CrossRef
[23] Mellor, A.L., et al. (2002) Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses. The Journal of Immunology, 168, 3771-3776.
[Google Scholar] [CrossRef] [PubMed]
[24] Mbongue, J.C., et al. (2015) The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel), 3, 703-729.
[Google Scholar] [CrossRef] [PubMed]
[25] Mantovani, A., et al. (2008) Cancer-Related Inflammation. Nature, 454, 436-444.
[Google Scholar] [CrossRef] [PubMed]
[26] Cersosimo, F., et al. (2020) Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. International Journal of Molecular Sciences, 21, Article 5207.
[Google Scholar] [CrossRef] [PubMed]
[27] Mantovani, A. and Allavena, P. (2015) The Interaction of Anticancer Therapies with Tumor-Associated Macrophages. Journal of Experimental Medicine, 212, 435-445.
[Google Scholar] [CrossRef] [PubMed]
[28] Bonavita, E., et al. (2015) Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Advances in Cancer Research, 128, 141-171.
[Google Scholar] [CrossRef] [PubMed]
[29] Leek, R.D., et al. (1996) Association of Macrophage Infiltration with Angiogenesis and Prognosis in Invasive Breast Carcinoma. Cancer Research, 56, 4625-4629.
[30] Tian, Y., Ke, Y. and Ma, Y. (2020) High Expression of Stromal Signatures Correlated with Macrophage Infiltration, Angiogenesis and Poor Prognosis in Glioma Microenvironment. PeerJ, 8, e9038.
[Google Scholar] [CrossRef] [PubMed]
[31] Murdoch, C., et al. (2008) The Role of Myeloid Cells in the Promotion of Tumour Angiogenesis. Nature Reviews Cancer, 8, 618-631.
[Google Scholar] [CrossRef] [PubMed]
[32] Su, B., et al. (2021) Let-7d Inhibits Intratumoral Macrophage M2 Polarization and Subsequent Tumor Angiogenesis by Targeting IL-13 and IL-10. Cancer Immunology, Immunotherapy, 70, 1619-1634.
[Google Scholar] [CrossRef
[33] Smeester, B.A., et al. (2020) PLX3397 Treatment Inhibits Constitutive CSF1R-Induced Oncogenic ERK Signaling, Reduces Tumor Growth, and Metastatic Burden in Osteosarcoma. Bone, 136, Article ID: 115353.
[Google Scholar] [CrossRef] [PubMed]
[34] Tap, W.D., et al. (2015) Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. The New England Journal of Medicine, 373, 428-437.
[Google Scholar] [CrossRef
[35] Molena, B., et al. (2011) Synovial Colony-Stimulating Factor-1 mRNA Expression in Diffuse Pigmented Villonodular Synovitis. Clinical and Experimental Rheumatology, 29, 547-550.
[36] Ries, C.H., et al. (2014) Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 25, 846-859.
[Google Scholar] [CrossRef] [PubMed]
[37] Butowski, N., et al. (2016) Orally Administered Colony Stimulating Factor 1 Receptor Inhibitor PLX3397 in Recurrent Glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium Phase II Study. Neuro-Oncology, 18, 557-564.
[Google Scholar] [CrossRef] [PubMed]
[38] von Tresckow, B., et al. (2015) An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clinical Cancer Research, 21, 1843-1850.
[Google Scholar] [CrossRef
[39] Pyonteck, S.M., et al. (2013) CSF-1R Inhibition Alters Macrophage Polarization and Blocks Glioma Progression. Nature Medicine, 19, 1264-1272.
[Google Scholar] [CrossRef] [PubMed]
[40] Cassier, P.A., et al. (2015) CSF1R Inhibition with Emactuzumab in Locally Advanced Diffuse-Type Tenosynovial Giant Cell Tumours of the Soft Tissue: A Dose-Escalation And Dose-Expansion Phase 1 Study. The Lancet Oncology, 16, 949-956.
[Google Scholar] [CrossRef
[41] Piaggio, F., et al. (2016) A Novel Liposomal Clodronate Depletes Tumor-Associated Macrophages in Primary and Metastatic Melanoma: Anti-Angiogenic and Anti-Tumor Effects. The Journal of Controlled Release, 223, 165-177.
[Google Scholar] [CrossRef] [PubMed]
[42] Hiraoka, K., et al. (2008) Inhibition of Bone and Muscle Metastases of Lung Cancer Cells by a Decrease in the Number of Monocytes/Macrophages. Cancer Science, 99, 1595-1602.
[Google Scholar] [CrossRef] [PubMed]
[43] Gazzaniga, S., et al. (2007) Targeting Tumor-Associated Macrophages and Inhibition of MCP-1 Reduce Angiogenesis and Tumor Growth in a Human Melanoma Xenograft. Journal of Investigative Dermatology, 127, 2031-2041.
[Google Scholar] [CrossRef] [PubMed]
[44] Zhou, Y., et al. (2020) Liposomal Clodronate Combined with Cisplatin or Sorafenib Inhibits Hepatocellular Carcinoma Cell Proliferation, Migration and Invasion by Suppressing FOXQ1 Expression. Cellular and Molecular Biology (Noisy-le-Grand), 66, 49-54.
[Google Scholar] [CrossRef
[45] Zhang, W., et al. (2010) Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects. Clinical Cancer Research, 16, 3420-3430.
[Google Scholar] [CrossRef
[46] Cassetta, L. and Pollard, J.W. (2018) Targeting Macrophages: Therapeutic Approaches in Cancer. Nature Reviews Drug Discovery, 17, 887-904.
[Google Scholar] [CrossRef] [PubMed]
[47] Deshmane, S.L., et al. (2009) Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. Journal of Interferon & Cytokine Research, 29, 313-326.
[Google Scholar] [CrossRef] [PubMed]
[48] Yoshimura, T. (2017) The Production of Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2 in Tumor Microenvironments. Cytokine, 98, 71-78.
[Google Scholar] [CrossRef] [PubMed]
[49] Li, L., et al. (2018) High Levels of CCL2 or CCL4 in the Tumor Microenvironment Predict Unfavorable Survival in Lung Adenocarcinoma. Thoracic Cancer, 9, 775-784.
[Google Scholar] [CrossRef] [PubMed]
[50] De la Fuente Lopez, M., et al. (2018) The Relationship between Chemokines CCL2, CCL3, and CCL4 with the Tumor Microenvironment and Tumor-Associated Macrophage Markers in Colorectal Cancer. Tumor Biology, 40.
[Google Scholar] [CrossRef] [PubMed]
[51] Avila, M.A. and Berasain, C. (2019) Targeting CCL2/CCR2 in Tumor-Infiltrating Macrophages: A Tool Emerging Out of the Box against Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 7, 293-294.
[Google Scholar] [CrossRef] [PubMed]
[52] Zheng, Y., et al. (2021) Epigenetic Silencing of Chemokine CCL2 Represses Macrophage Infiltration to Potentiate Tumor Development in Small Cell Lung Cancer. Cancer Letters, 499, 148-163.
[Google Scholar] [CrossRef] [PubMed]
[53] Steinberger, K.J., et al. (2020) Stress-Induced Norepinephrine Downregulates CCL2 in Macrophages to Suppress Tumor Growth in a Model of Malignant Melanoma. Cancer Prevention Research (Phila), 13, 747-760.
[Google Scholar] [CrossRef
[54] Yao, M., et al. (2017) Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts. Translational Oncology, 10, 734-743.
[Google Scholar] [CrossRef] [PubMed]
[55] Loberg, R.D., et al. (2007) CCL2 as an Important Mediator of Prostate Cancer Growth in Vivo through the Regulation of Macrophage Infiltration. Neoplasia, 9, 556-562.
[Google Scholar] [CrossRef] [PubMed]
[56] Bonapace, L., et al. (2014) Cessation of CCL2 Inhibition Accelerates Breast Cancer Metastasis by Promoting Angiogenesis. Nature, 515, 130-133.
[Google Scholar] [CrossRef] [PubMed]
[57] Hitchcock, J.R. and Watson, C.J. (2015) Anti-CCL2: Building a Reservoir or Opening the Floodgates to Metastasis? Breast Cancer Research, 17, Article No. 68.
[Google Scholar] [CrossRef] [PubMed]
[58] Lebrecht, A., et al. (2004) Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer. Tumor Biology, 25, 14-17.
[Google Scholar] [CrossRef] [PubMed]
[59] Loberg, R.D., et al. (2007) Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression in Vivo. Cancer Research, 67, 9417-9424.
[Google Scholar] [CrossRef
[60] Moisan, F., et al. (2014) Enhancement of Paclitaxel and Carboplatin Therapies by CCL2 Blockade in Ovarian Cancers. Molecular Oncology, 8, 1231-1239.
[Google Scholar] [CrossRef] [PubMed]
[61] Nywening, T.M., et al. (2016) Targeting Tumour-Associated Macrophages with CCR2 Inhibition in Combination with FOLFIRINOX in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single-Centre, Open-Label, Dose-Finding, Non-Randomised, Phase 1b Trial. The Lancet Oncology, 17, 651-662.
[Google Scholar] [CrossRef
[62] Chen, J., et al. (2017) SLAMF7 Is Critical for Phagocytosis of Haematopoietic Tumour Cells via Mac-1 Integrin. Nature, 544, 493-497.
[Google Scholar] [CrossRef] [PubMed]
[63] Xiao, Z., et al. (2015) Antibody Mediated Therapy Targeting CD47 Inhibits Tumor Progression of Hepatocellular Carcinoma. Cancer Letters, 360, 302-309.
[Google Scholar] [CrossRef] [PubMed]
[64] Edris, B., et al. (2012) Antibody Therapy Targeting the CD47 Protein Is Effective in a Model of Aggressive Metastatic Leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 109, 6656-6661.
[Google Scholar] [CrossRef] [PubMed]
[65] Weiskopf, K., et al. (2016) CD47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small- Cell Lung Cancer. Journal of Clinical Investigation, 126, 2610-2620.
[Google Scholar] [CrossRef
[66] Liu, R., et al. (2017) CD47 Promotes Ovarian Cancer Progression by Inhibiting Macrophage Phagocytosis. Oncotarget, 8, 39021-39032.
[Google Scholar] [CrossRef] [PubMed]
[67] Wu, Z., et al. (2019) Identification of Glutaminyl Cyclase Isoenzyme isoQC as a Regulator of SIRPalpha-CD47 Axis. Cell Research, 29, 502-505.
[Google Scholar] [CrossRef] [PubMed]
[68] Logtenberg, M.E.W., et al. (2019) Glutaminyl Cyclase Is an Enzymatic Modifier of the CD47-SIRPalpha Axis and a Target for Cancer Immunotherapy. Nature Medicine, 25, 612-619.
[Google Scholar] [CrossRef] [PubMed]
[69] Ansell, S.M., et al. (2021) Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research, 27, 2190-2199.
[70] Petrova, P.S., et al. (2017) TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clinical Cancer Research, 23, 1068-1079.
[Google Scholar] [CrossRef
[71] Kaczanowska, S., Joseph, A.M. and Davila, E. (2013) TLR Agonists: Our Best Frenemy in Cancer Immunotherapy. Journal of Leukocyte Biology, 93, 847-863.
[Google Scholar] [CrossRef] [PubMed]
[72] Le Mercier, I., et al. (2013) Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment. Cancer Research, 73, 4629-4640.
[Google Scholar] [CrossRef
[73] Singh, M., et al. (2014) Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation. The Journal of Immunology, 193, 4722-4731.
[Google Scholar] [CrossRef] [PubMed]
[74] Vacchelli, E., et al. (2016) Trial Watch: Immunotherapy plus Radiation Therapy for Oncological Indications. Oncoimmunology, 5, e1214790.
[Google Scholar] [CrossRef
[75] Menzies, S., Mc Menamin, M. and Barry, R. (2017) Lentigo Maligna Successfully Treated with Combination Therapy of Topical Tazarotene and Imiquimod. Clinical and Experimental Dermatology, 42, 468-470.
[Google Scholar] [CrossRef] [PubMed]
[76] Klichinsky, M., et al. (2020) Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Nature Biotechnology, 38, 947-953.
[Google Scholar] [CrossRef] [PubMed]
[77] Zhang, L., et al. (2020) Pluripotent Stem Cell-Derived CAR-Macrophage Cells with Antigen-Dependent Anti-Cancer Cell Functions. Journal of Hematology & Oncology, 13, Article No. 153.
[Google Scholar] [CrossRef] [PubMed]
[78] Hirsch, E., et al. (2000) Central Role for G Protein-Coupled Phosphoinositide 3-Kinase Gamma in Inflammation. Science, 287, 1049-1053.
[Google Scholar] [CrossRef] [PubMed]
[79] Kaneda, M.M., et al. (2016) PI3Kgamma Is a Molecular Switch That Controls Immune Suppression. Nature, 539, 437-442.
[Google Scholar] [CrossRef] [PubMed]